Literature DB >> 22930550

Inhibition of bacterial dihydrofolate reductase by 6-alkyl-2,4-diaminopyrimidines.

Baskar Nammalwar1, Christina R Bourne, Richard A Bunce, Nancy Wakeham, Philip C Bourne, Kal Ramnarayan, Shankari Mylvaganam, K Darrell Berlin, Esther W Barrow, William W Barrow.   

Abstract

(±)-6-Alkyl-2,4-diaminopyrimidine-based inhibitors of bacterial dihydrofolate reductase (DHFR) have been prepared and evaluated for biological potency against Bacillus anthracis and Staphylococcus aureus. Biological studies revealed attenuated activity relative to earlier structures lacking substitution at C6 of the diaminopyrimidine moiety, though minimum inhibitory concentration (MIC) values are in the 0.125-8 μg mL(-1) range for both organisms. This effect was rationalized from three- dimensional X-ray structure studies that indicate the presence of a side pocket containing two water molecules adjacent to the main binding pocket. Because of the hydrophobic nature of the substitutions at C6, the main interactions are with protein residues Leu 20 and Leu 28. These interactions lead to a minor conformational change in the protein, which opens the pocket containing these water molecules such that it becomes continuous with the main binding pocket. These water molecules are reported to play a critical role in the catalytic reaction, highlighting a new area for inhibitor expansion within the limited architectural variation at the catalytic site of bacterial DHFR.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  6-alkylpyrimidines; Bacillus anthracis; Staphylococcus aureus; antibiotics; dihydrofolate reductases; inhibitors

Mesh:

Substances:

Year:  2012        PMID: 22930550      PMCID: PMC3570588          DOI: 10.1002/cmdc.201200291

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  27 in total

1.  The antibiotics market.

Authors:  Bashar Hamad
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

2.  Up against the wall.

Authors:  Christian Torres
Journal:  Nat Med       Date:  2010-06       Impact factor: 53.440

Review 3.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Synthesis and testing of 5-benzyl-2,4-diaminopyrimidines as potential inhibitors of leishmanial and trypanosomal dihydrofolate reductase.

Authors:  Shafinaz F Chowdhury; Ramon Hurtado Guerrero; Reto Brun; Luis M Ruiz-Perez; Dolores Gonzalez Pacanowska; Ian H Gilbert
Journal:  J Enzyme Inhib Med Chem       Date:  2002-10       Impact factor: 5.051

5.  Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.

Authors:  C R Bourne; E W Barrow; R A Bunce; P C Bourne; K D Berlin; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2010-07-06       Impact factor: 5.191

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  PHENIX: a comprehensive Python-based system for macromolecular structure solution.

Authors:  Paul D Adams; Pavel V Afonine; Gábor Bunkóczi; Vincent B Chen; Ian W Davis; Nathaniel Echols; Jeffrey J Headd; Li-Wei Hung; Gary J Kapral; Ralf W Grosse-Kunstleve; Airlie J McCoy; Nigel W Moriarty; Robert Oeffner; Randy J Read; David C Richardson; Jane S Richardson; Thomas C Terwilliger; Peter H Zwart
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

Review 8.  Antibiotics for emerging pathogens.

Authors:  Michael A Fischbach; Christopher T Walsh
Journal:  Science       Date:  2009-08-28       Impact factor: 47.728

9.  Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity.

Authors:  Christina R Bourne; Richard A Bunce; Philip C Bourne; K Darrell Berlin; Esther W Barrow; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

Review 10.  Rational approaches to improving selectivity in drug design.

Authors:  David J Huggins; Woody Sherman; Bruce Tidor
Journal:  J Med Chem       Date:  2012-01-12       Impact factor: 7.446

View more
  5 in total

1.  Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis.

Authors:  Baskar Nammalwar; Christina R Bourne; Nancy Wakeham; Philip C Bourne; Esther W Barrow; N Prasad Muddala; Richard A Bunce; K Darrell Berlin; William W Barrow
Journal:  Bioorg Med Chem       Date:  2014-11-11       Impact factor: 3.641

2.  Evaluation of New Dihydrophthalazine-Appended 2,4-Diaminopyrimidines against Bacillus anthracis: Improved Syntheses Using a New Pincer Complex.

Authors:  Nagendra Prasad Muddala; Baskar Nammalwar; Subhashini Selvaraju; Christina R Bourne; Mary Henry; Richard A Bunce; K Darrell Berlin; Esther W Barrow; William W Barrow
Journal:  Molecules       Date:  2015-04-21       Impact factor: 4.411

3.  MoS2/cellulose-doped ZnO nanorods for catalytic, antibacterial and molecular docking studies.

Authors:  Muhammad Ikram; Muhammad Imran; Shoukat Hayat; Anum Shahzadi; Ali Haider; Sadia Naz; Anwar Ul-Hamid; Walid Nabgan; Iqra Fazal; Salamat Ali
Journal:  Nanoscale Adv       Date:  2021-11-01

4.  The structure and competitive substrate inhibition of dihydrofolate reductase from Enterococcus faecalis reveal restrictions to cofactor docking.

Authors:  Christina R Bourne; Nancy Wakeham; Nicole Webb; Baskar Nammalwar; Richard A Bunce; K Darrell Berlin; William W Barrow
Journal:  Biochemistry       Date:  2014-02-11       Impact factor: 3.162

5.  Synthesis and biological evaluation of 2,4-diaminopyrimidine-based antifolate drugs against Bacillus anthracis.

Authors:  Baskar Nammalwar; N Prasad Muddala; Christina R Bourne; Mary Henry; Philip C Bourne; Richard A Bunce; Esther W Barrow; K Darrell Berlin; William W Barrow
Journal:  Molecules       Date:  2014-03-17       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.